Advanced Filters
noise

Lincoln, Rhode Island Clinical Trials

A listing of Lincoln, Rhode Island clinical trials actively recruiting patient volunteers.

Found 324 clinical trials
A Alison Tovar, PhD

Strong Families Start at Home/Familias Fuertes Comienzan en Casa

The goal of this clinical trial is to test the ability of a home-based parental nutrition intervention to improve diet quality in preschool aged children within low-income, Latinx/Hispanic families. The main questions it aims to answer are: Does this enhanced intervention change children's diet quality? Does this enhanced intervention change …

18 years of age All Phase N/A

Mindfulness, Optimism, and Resilience for Perinatal Health and Equity Study

Dispositional optimism (the general assumption that more good things than bad will occur across various life domains) has been tied to improved somatic and mental health outcomes. Dispositional optimism is malleable, although prior interventions have been time and resource intensive and thus are not well-tailored to the peripartum period. The …

18 years of age Female Phase N/A
L Lauren Vaile

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

The objective of this clinical trial is to evaluate the effect of a nutritional formula composed of carbohydrates and proteins on gastric emptying in elderly individuals aged between 60 and 90 years. The main questions this study aims to answer are: Does the nutritional formula composed of carbohydrates and proteins …

18 years of age All Phase 2
J Jeff Bullock

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The …

18 - 70 years of age All Phase 4
T Tiffany Hoefler

Clinical Trial on Agitation in Alzheimer's Dementia

The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

60 years of age All Phase 2
K Kathryn E Demos McDermott, PhD

Cognitive Strategies for Weight Loss

The goal of this clinical trial is to compare weight change and other related outcomes associated with three different behavioral weight loss interventions (STANDARD Behavioral, PREVENT, and PROMOTE) in adults with obesity. The main questions it aims to answer are: Which of the three Internet-delivered weight loss programs results in …

18 - 70 years of age All Phase N/A
L Leigh R Hochberg, MD, PhD

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

18 - 80 years of age All Phase N/A
E Erin Kaye Donahue, PhD

Pilot/Pivotal Study of DBS+Rehab After Stroke

The RESTORE Stroke Study will evaluate the safety and effectiveness of DBS+Rehab for treating arm weakness and reduced function after a stroke.

21 years of age All Phase N/A
K Krista Mueller

Neuroblastoma Maintenance Therapy Trial

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 …

1 - 30 years of age All Phase 2
M Myo Zaw

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced …

18 years of age All Phase 1/2

Simplify language using AI